Aurora Cannabis Inc.

NasdaqCM:ACB Stock Report

Market Cap: US$244.0m

Aurora Cannabis Past Earnings Performance

Past criteria checks 0/6

Aurora Cannabis has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 1.4% per year.

Key information

35.5%

Earnings growth rate

52.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-1.4%
Return on equity-5.6%
Net Margin-10.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Aurora Cannabis: Revving Up To Profitability

Aug 08

Aurora launches new cannabis products for adult and medical-use

Oct 17

Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes

Oct 07

Aurora Cannabis Q4 2022 Earnings Preview

Sep 19

Aurora Cannabis: Don't Let Your Money Go Up In Smoke

Aug 25

Why Did Aurora Cannabis Stock Crash In May; Can It Recover?

Jun 13

Recent Developments Do Not Change Our Stance On Aurora Cannabis

May 13

Aurora Cannabis: A Train Wreck Desperate For Help

May 05

Aurora Cannabis: The Fallen Pot Giant That Still Can't Find Its Way

Feb 17

Aurora Cannabis Vs. HEXO: Which Is The Better Cannabis Stock?

Dec 17

Tilray Vs. Aurora Cannabis: How To Compare These Cannabis Stocks

Oct 11

Aurora Cannabis: Investors Should Have No Confidence In This Company

Sep 28

Is Aurora Cannabis Stock A Buy Or Sell Before Upcoming Earnings? Buy The U.S. Opportunity

Sep 16

Aurora Cannabis Is A Pass For Now, Although We Are Bullish On The Industry

Jun 05

Aurora Cannabis: Extreme Downside Case Averted

Feb 02

Revenue & Expenses Breakdown

How Aurora Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ACB Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24297-301613
30 Jun 24279-301603
31 Mar 24270-551574
31 Dec 23266-1161744
30 Sep 23262-1531745
30 Jun 23248-1951675
31 Mar 23224-7931706
31 Dec 22212-1,7481638
30 Sep 22210-1,7571808
30 Jun 22221-1,71817610
31 Mar 22226-1,23318511
31 Dec 21231-38118912
30 Sep 21238-60718813
30 Jun 21245-69219511
31 Mar 21257-2,38720616
31 Dec 20275-2,35924118
30 Sep 20263-3,34230023
30 Jun 20269-3,23134626
31 Mar 20299-1,40537224
31 Dec 19291-1,43039722
30 Sep 19290-38537617
30 Jun 19246-29436515
31 Mar 19168-21132710
31 Dec 18119-722537
30 Sep 18771741875
30 Jun 1855721102
31 Mar 1842-13691
31 Dec 17317450
30 Sep 1723-4310
30 Jun 1718-13250
31 Mar 1713-16190
31 Dec 168-13130
30 Sep 165-1081
30 Jun 161-661
31 Mar 160051
31 Dec 150-341
30 Sep 150-1041
30 Jun 150-1040

Quality Earnings: ACB is currently unprofitable.

Growing Profit Margin: ACB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ACB is unprofitable, but has reduced losses over the past 5 years at a rate of 35.5% per year.

Accelerating Growth: Unable to compare ACB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: ACB has a negative Return on Equity (-5.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies